Literature DB >> 2775039

Prospective evaluation of a flexible protocol for starting treatment with warfarin and predicting its maintenance dose.

D G Cosh1, C K Moritz, K J Ashman, R J Dally, A S Gallus.   

Abstract

We have evaluated a flexible warfarin dose induction protocol by monitoring its performance in 100 elderly inpatients. The protocol (designed by Fennerty et al., has two aims: (a) to move the prothrombin time (PT) ratio smoothly and quickly into its therapeutic range, and (b) to predict the steady-state warfarin requirement from the PT ratio measured on the fourth treatment day. It proved simple to use and reasonably successful, since after four days, 67/100 patients had achieved a therapeutic level of PT ratio, nine exceeded the therapeutic range, and 24 remained sub-therapeutic, while none had bled due to excessive anticoagulation. Maintenance dose prediction was tested by comparing the predicted and observed maintenance doses in patients within the 'therapeutic range' of PT ratio after various median times of treatment. After ten days, the observed dose was within 1 mg of that predicted in 65/86 patients (76%). This proportion became 57/77 (74%) after 18 days, and 49/79 (62%) after 34 days.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2775039     DOI: 10.1111/j.1445-5994.1989.tb00243.x

Source DB:  PubMed          Journal:  Aust N Z J Med        ISSN: 0004-8291


  9 in total

Review 1.  Use of oral anticoagulants in older patients.

Authors:  J L Sebastian; D D Tresch
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

Review 2.  The future prospects of pharmacogenetics in oral anticoagulation therapy.

Authors:  Farhad Kamali; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

3.  Control of warfarin therapy.

Authors:  A Fennerty; P A Routledge
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

Review 4.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

Review 5.  Warfarin therapy: in need of improvement after all these years.

Authors:  Stephen E Kimmel
Journal:  Expert Opin Pharmacother       Date:  2008-04       Impact factor: 3.889

Review 6.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

7.  Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans.

Authors:  H Schelleman; J Chen; Z Chen; J Christie; C W Newcomb; C M Brensinger; M Price; A S Whitehead; C Kealey; C F Thorn; F F Samaha; S E Kimmel
Journal:  Clin Pharmacol Ther       Date:  2008-07-02       Impact factor: 6.875

8.  Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study.

Authors:  Andrea L Jorgensen; Sameh Al-Zubiedi; Jieying Eunice Zhang; Andrew Keniry; Anita Hanson; Dyfrig A Hughes; Diane van Eker; Lisa Stevens; Karen Hawkins; Cheng H Toh; Farhad Kamali; Ann K Daly; David Fitzmaurice; Alison Coffey; Paula R Williamson; Brian Kevin Park; Panos Deloukas; Munir Pirmohamed
Journal:  Pharmacogenet Genomics       Date:  2009-10       Impact factor: 2.089

9.  Effect of age upon the induction and maintenance of anticoagulation with warfarin.

Authors:  J R Gladman; G Dolan
Journal:  Postgrad Med J       Date:  1995-03       Impact factor: 2.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.